London pre-open: Stocks seen muted ahead of US inflation data

by | Feb 10, 2022

London stocks were set for a muted open on Thursday as investors eye the latest US inflation data.
The FTSE 100 was called to open unchanged at 7,643.

CMC Markets analyst Michael Hewson said: “We saw another strong session for markets in Europe yesterday, with the FTSE100 putting in a new two year high, with the rest of Europe also putting in some good gains.

“US markets also saw a solid session led by the Nasdaq 100 which retested its 200-day MA for the first time since last week’s failure, which in turn is expected to translate into a mixed lead for today’s European open.

“Today’s US inflation report could well be the catalyst that determines whether the Nasdaq 100 breaks back above that key 200-day moving average level in the next few hours.”

The US consumer price index for January is due out at 1330 GMT.

In corporate news, AstraZeneca swung to a fourth-quarter loss as higher costs more than offset a surge in revenue boosted by sales of the company’s Covid-19 vaccine.

The drugs company posted a $636m pre-tax loss for the three months to the end of December from a $1.49bn profit a year earlier as revenue rose 62% to $12bn. AstraZeneca declared a second interim dividend of $1.97 a share, taking the annual payout to $2.87.

AstraZeneca said it expected revenue to rise by a mid-teens percentage in 2022 and for core earnings per share to increase by a percentage in the mid-to-high 20s.

Retailer Watches of Switzerland said that both third-quarter and year-to-date revenues had grown, leading the firm to expect full-year revenues and profits to trend more towards the top end of guidance.

The company said third-quarter group revenues were up 27.9% at £348.1m, while year-to-date revenues were 38% stronger at £934.3m as demand for luxury watches continued to be “very strong” in both the UK and the US, consistently exceeding supply.

Consumer products conglomerate Unilever said fourth-quarter underlying sales grew 4.9% and announced a €3bn share buyback, as it warned of the continuing impact of cost inflation and the Covid-19 pandemic.

In the first results since its failed bid for GlaxoSmithKline’s consumer health business, the maker of Magnum ice-cream said it expected underlying sales growth in 2022 to be 4.5% – 6.5%. Pricing would continue to be strong, with some impact on volume as a result.

The underlying operating margin for 2022 was expected fall by 140 – 240 basis points and maintained between 16% – 17%, with the main impact on the first half.

“We expect margin to be restored after 2022, with the bulk coming back in 2023 and the rest in 2024,” Unilever said.

Related articles

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x